(Reuters): The US Food and Drug Administration approved Mirati Therapeutics Inc’s (MRTX.O) lung cancer drug adagrasib, the company said on Monday, sending its shares up more than 8% in extended trading. Mirati’s drug has been approved for treating adult patients with advanced lung cancer as determined by an FDA-approved test, who have received at least one prior systemic therapy. …